Moderna, Inc. (MRNA)
3 Things You Need to Know if You Buy Moderna Today
Based on its share price, down 75% in the last three years, it's easy to write off Moderna (MRNA -2.31%) as a biotech that'll never recover its former glory -- which it built on the success of its coronavirus vaccine program. But where there are widespread bearish sentiments about a stock, there's also often an opportunity for investors who are willing to focus on the long term and appreciate that things won't always be like they are now.
A norovirus vaccine could be on the horizon as cases rise
Moderna is testing a norovirus vaccine in a phase three trial, with results available as soon as this year. Norovirus cases are on the rise this winter, with outbreaks already up more than 30% by December, per data from the Centers for Disease Control and Prevention.
Moderna Surges After Larry Ellison Calls Out The Potential Of AI In Cancer Vaccines
Moderna stock surged Wednesday after Oracle Chairman Larry Ellison praised the potential of AI in developing medicines. The post Moderna Surges After Larry Ellison Calls Out The Potential Of AI In Cancer Vaccines appeared first on Investor's Business Daily.
After a Reset Year, Is Moderna Stock Poised for a Comeback?
Biotechnology company Moderna Inc. NASDAQ: MRNA gained the spotlight in the medical sector as a leader in the race toward a COVID-19 vaccine. Its messenger RNA (mRNA) technology garnered acclaim as a next-generation therapy.
3-Stock Lunch: 3M, Moderna, & T-Mobile
Eva Ados, ERshares COO and chief investment strategist, joins CNBC's 'Power Lunch' to share outlooks on three stocks.
Why Is Moderna Stock Trading Higher On Tuesday?
Tuesday, Moderna Inc MRNA stock is trading higher with a session volume of 8.0 million as per data from Benzinga Pro.
Moderna Stock Jumps as Biotech Gets $590M From US To Develop Bird-Flu Vaccine
Shares of Moderna (MRNA) took off Tuesday when the biotech firm announced that the U.S. government has awarded it more than a half a billion dollars to develop a vaccine that can be used against bird flu.
Underperforming Moderna Stock Boosted by Bird Flu Vaccine
Moderna Inc (NASDAQ:MRNA) stock is surging today, up 8.7% at $37.02 at last glance, after the vaccine maker was awarded $590 million from the U.S. Health and Human Services Department to speed up the development of its bird flu vaccine, as the virus spreads rapidly throughout the country.
Where Will Moderna Be in 3 Years?
As Moderna (MRNA 6.28%) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural for investors to wonder about where the biotech will go in the near future.
Moderna Secures $590M Funding From U.S. Government for Bird Flu Jab
MRNA intends to use the funds to support the development of its mRNA-based bird flu shot and expand clinical studies for additional subtypes of pandemic influenza.
Despite Setbacks, Moderna Sees Opportunity In Avian Flu, Merck Partnership
Moderna's recent stumbles make the company an acquisition target. Merck desperately needs Moderna's mRNA-based Personal Cancer Vaccines ("PCVs") to extend KEYTRUDA's patent protection beyond 2028. Merck stands to lose $62 billion over four years following the loss of exclusivity on KEYTRUDA, making Moderna's $13 billion market cap a bargain.
Is Moderna Stock a Buy?
Share prices of Moderna (MRNA 0.89%) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The biotech, renowned for its pioneering development of vaccines based on messenger RNA (mRNA), has struggled to manage weak sales of COVID-19 vaccine and sluggish market adoption of its new shot for respiratory syncytial virus (RSV).
